US Tells High Court Myriad's Isolated DNA Can't Be Patented

Law360, New York (February 1, 2013, 5:54 PM EST) -- The federal government told the U.S. Supreme Court on Thursday that breast cancer genes isolated by Myriad Genetics Inc. cannot be patented because they are no different from genes that exist in nature, and that patents on isolated DNA should not be issued.

U.S. Solicitor General Donald Verrilli filed an amicus brief supporting many of the positions taken by the American Civil Liberties Union, which is appealing a Federal Circuit ruling that Myriad's isolated DNA is a manmade composition eligible for a patent.

"Isolated but otherwise unmodified DNA is not patent-eligible," the government wrote. "The public's ability to study and use...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS